CATHETER PRECISION INC (VTAK)
AMEXHealth CareMedical - DevicesSnapshot 2026-09-04
$0.21+6.82%
Close 2026-09-04 · 1-day change
AMEXHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · VTAK
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on driving strong revenue growth through expansion in medical device and aviation segments.
Stated as a priority in 3 of last 3 quarters. Revenue grew from $238,000 in 2025-Q4 to $432,000 in 2026-Q1 (200% YoY growth) and further to $1,019,000 in 2026-Q2. This trajectory shows delivering strong revenue growth as management emphasized.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Revenue increased to $1,019,000 in Q2 2026, continuing growth trajectory.”
“First quarter revenue grew 200% year-over-year to $432,000.”
“Revenue was $238,000 in Q4 2025, showing growth from prior quarters.”
Continue capital allocation through private placements, equity sales, and rights modifications to support growth and operations.
Capital allocation activities were stated in 4 of last 4 quarters, including multiple private placements and equity sales raising multimillion-dollar proceeds. These actions support operational funding but net losses persist, indicating mixed progress on capital efficiency.
“Completed sale of 2,821 shares of Series C-4 Convertible Preferred Stock for $2.8M.”
“Entered into securities purchase agreement for Series C-1 Convertible Preferred Stock private placement.”
“Completed sale of 3,470 shares of Series C-2 Convertible Preferred Stock for $3.47M.”
“Material modifications to rights of security holders disclosed.”
Focus on margin improvement through revenue growth and operating discipline in medical device and aviation segments.
Management stated improving gross profit in 3 of last 3 quarters. Gross profit rose from $132,000 in 2025-Q1 to $390,000 in 2026-Q1, then was $98,000 in 2026-Q2 (seasonal or segment mix effects possible). Overall, trajectory shows delivering margin improvement alongside revenue growth.
“Gross profit was $98,000 in Q2 2026, reflecting margin improvement.”
“Gross profit increased to $390,000 in Q1 2026 from prior quarters.”
“Gross profit was $218,000 in Q4 2025, up from earlier periods.”
Over the trailing year it converted 0.99x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates, the broad stock market (low R² over the window).
32 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.